About Unicycive
Unicycive is a publicly listed company based in San Francisco (United States) founded in 2016. Small molecule therapies for kidney diseases are developed. Unicycive has raised $1.55 million across 5 funding rounds from investors including Octagon Capital Advisors, Great Point Partners and Logos Capital. The company has 22 employees. Its website unicycive.com draws about 15 thousand monthly visits. Unicycive offers products and services including Oxylanthanum Carbonate (OLC) and UNI-494. Its focus areas include Life Sciences, Metabolic Diseases, Drugs and Renal Disorders. Its competitors include Akebia Therapeutics and Arthrosi Therapeutics; 2 of its 2 listed competitors have raised funding.
Company details
Unicycive was founded in 2016 and is based in San Francisco, United States. Focus is placed on developing small molecule therapies targeting kidney diseases within the biotechnology sector. The lead product, UNI 494, is under investigation for both acute and chronic kidney conditions. Oxylanthanum Carbonate is also being advanced for managing hyperphosphatemia. Operations center on therapeutic innovation for renal health challenges.
- Headquarters San Francisco, United States
- Employees 22
- Stage Public
- SectorsHealthcare
- Email••••••••
- Website unicycive.com
- Social LinkedIn X YouTube
- Legal Name Unicycive Therapeutics, Inc.
- Net Profit-$26.55 M (USD)27.7as on Dec 31, 2025
- EBITDA-$28.95 M (USD)8.66as on Dec 31, 2025
- Total Equity Funding$1.55M (USD)
in 5 rounds
- Latest Funding Round$50M (USD), Post-IPO
Mar 2024
- InvestorsOctagon Capital Advisors
& 6 more
- Employee Count22
Products & Services of Unicycive
Unicycive offers a comprehensive portfolio of products and services, including Oxylanthanum Carbonate (OLC) and UNI-494.
Treats hyperphosphatemia using proprietary nanoparticle technology.
Targets mitochondria for acute kidney injury treatment.
Apps and channels of Unicycive
its YouTube channel Unicycive has 81 subscribers and 30 videos.
Videos from Unicycive
The most watched videos on Unicycive's YouTube channel, Unicycive (81 subscribers). Click a video to play it here.
More on Unicycive.
Funding Insights of Unicycive
Unicycive has successfully raised a total of $1.55M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $50 million completed in March 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1.55M
- Total Rounds 5
- Last Round Post-IPO — $50M
- First Round $420,000
(Mar 2019)
- Investors Count 7
All 5 funding rounds of Unicycive with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2024 | $50M | Post-IPO | – | – | |
| Mar 2023 | $30.19M | Post-IPO | – | – | – |
| Jun 2020 | $604,140 | Seed | – | – | – |
| Aug 2019 | $526,950 | Seed | – | – | – |
| Mar 2019 | $420,000 | Seed | – | – | – |
7 investors in total: 7 institutional.
Investors in Unicycive
Unicycive has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Octagon Capital Advisors, Great Point Partners and Logos Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments in healthcare startups are managed by Octagon Capital Advisors. | octagoninvestments.com | New York, United States | ||
Private equity firm focused on company buyouts | gppfunds.com | Greenwich, United States | ||
Private equity fund focused on the biotechnology sector | logoscapital.com | San Francisco, United States | ||
| velancapital.com | ||||
Venture capital and private equity firm | vivocapital.com | Palo Alto, United States | ||
Fundamentally-driven firm investing in micro-cap stocks with long and short strategies. | 2004 | nantahalapartners.com | New Canaan, United States | |
Manages hedge funds with a focus on multiple investment strategies. | 2005 | walleyecapital.com | Plymouth, United States |
Investor details for Unicycive
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Unicycive
13 people are tracked at Unicycive (12 in leadership, 1 in team); the tracked headcount is 22.
| Name | Role | Group |
|---|---|---|
Shalabh Gupta, MD | Founder & CEO | Leadership |
Atul Khare, Ph.D., M.B.A. | Vice President, Scientific Affairs | Leadership |
Doug Jermasek | Executive Vice President, Corporate Strategy | Leadership |
Guru Reddy | Vice President, Preclinical R&D | Leadership |
John Townsend | Chief Financial Officer | Leadership |
Teresa Miller | Senior Director of Analytical and Pharmaceutical Development | Leadership |
Steve Hasal | Sr. Director, Clinical Sciences | Leadership |
Satya Medicherla | Vice President, Pre-clinical Pharmacology | Leadership |
Hannah Haddox | Executive Assistant to Chief Executive Officer | Leadership |
Vincent Fisher | Executive Director - Global Marketing & New Product Planning | Leadership |
Edgar Trinidad | Senior Director, Technical Accounting | Leadership |
Sanjay Mourya | Senior Director Clinical Operations | Leadership |
Pramod Gupta | EVP, Pharmaceutical & Business Operations, Unicycive Therapeutics, Inc. | Team |
Complete people profiles for Unicycive
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Unicycive
Unicycive is a publicly listed company on the NASDAQ with ticker symbol UNCY in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date13 Jul 2021
- Listed onNASDAQ: UNCY
- Listed entityUnicycive Therapeutics, Inc.
- Exchange sectorHealth technology
- ISINUS90466Y2028
- Share price$3.73 (-7.9% on the day) · 2026-10-13
- Market capitalisation$103.9M
- EPS (diluted, trailing year)$-1.60
- Volume (last session)1,840,063
Financials of Unicycive
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | -$26.6M | -$28.9M | |
| 2024 | -$36.7M | -$31.7M | |
| 2023 | $675,000 | -$30.5M | -$20.5M |
| 2022 | $951,000 | -$18.1M | -$18.1M |
| 2021 | -$10.0M | -$9.0M |
Detailed financial statements for Unicycive
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Unicycive
4 dated milestones of Unicycive across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Unicycive is founded.
- Funding First funding round of $420K.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $50.0M.
Competitors of Unicycive
Unicycive has 2 listed competitors in our database, 2 of them funded. They include Akebia Therapeutics and Arthrosi Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| akebia.com | 2007 | Cincinnati, United States | $91M | 205 | Therapeutics for kidney disease treatment are developed by Akebia Therapeutics. | |
| arthrosi.com | 2017 | Irvine, United States | $200.87M | 11 | Therapeutics for gout, kidney diseases, and oncology are developed. |
Detailed competitors of Unicycive
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Unicycive
The website of Unicycive (unicycive.com) receives about 14.8K visits a month.
- Monthly visits14.8K
▼ 18.7% vs previous month
Top companies in Metabolic Diseases
3 companies that operate in the same segment as Unicycive (Metabolic Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Satiety induction through digestable gastric balloon introduced via a swallowed capsule | 2009 | Wellesley, Massachusetts, United States | USD 174.04 M | USD 32.11 M | 137 | |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies | 2010 | Boston, Massachusetts, United States | USD 84 M | USD 189.76 M | 283 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Unicycive
Complete news archive for Unicycive
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Unicycive
Unicycive was founded in 2016 and raised its 1st funding round 3 years after it was founded.
Unicycive is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Unicycive is a funded company, having raised a total of $1.55M across 5 funding rounds to date. The company's 1st funding round was a Seed of $420K, raised on Mar 2019.
Unicycive has 22 employees.
Unicycive was founded in 2016 and is based in San Francisco, United States. Focus is placed on developing small molecule therapies targeting kidney diseases within the biotechnology sector. The lead product, UNI 494, is under investigation for both acute and chronic kidney conditions. Oxylanthanum Carbonate is also being advanced for managing hyperphosphatemia. Operations center on therapeutic innovation for renal health challenges.
Unicycive's top competitors include Akebia Therapeutics and Arthrosi Therapeutics.
Unicycive offers Oxylanthanum Carbonate (OLC) and UNI-494.
Yes, Unicycive is publicly traded on NASDAQ under the ticker symbol UNCY.
Unicycive has 7 investors. Key investors include Octagon Capital Advisors, Great Point Partners, Logos Capital, Nantahala Capital Management, and Velan Capital.